NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) Short Interest Down 43.1% in July

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) saw a significant drop in short interest in July. As of July 15th, there was short interest totalling 52,700 shares, a drop of 43.1% from the June 30th total of 92,600 shares. Based on an average daily trading volume, of 59,500 shares, the short-interest ratio is presently 0.9 days. Approximately 16.2% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, Maxim Group initiated coverage on shares of NeuroBo Pharmaceuticals in a report on Wednesday, May 8th. They issued a “buy” rating and a $10.00 target price for the company.

Insider Buying and Selling at NeuroBo Pharmaceuticals

In related news, major shareholder St Co. Ltd Dong-A bought 2,544,530 shares of the company’s stock in a transaction on Sunday, June 23rd. The stock was bought at an average cost of $3.13 per share, with a total value of $7,964,378.90. Following the completion of the acquisition, the insider now owns 5,348,229 shares in the company, valued at approximately $16,739,956.77. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.54% of the stock is currently owned by corporate insiders.

NeuroBo Pharmaceuticals Stock Up 1.3 %

Shares of NRBO stock traded up $0.06 during trading hours on Friday, hitting $4.15. The company’s stock had a trading volume of 14,553 shares, compared to its average volume of 615,435. The business has a fifty day moving average of $4.29 and a 200-day moving average of $4.23. NeuroBo Pharmaceuticals has a twelve month low of $2.90 and a twelve month high of $6.75.

NeuroBo Pharmaceuticals (NASDAQ:NRBO) last released its quarterly earnings results on Thursday, May 9th. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($0.95) by ($0.37). Equities analysts expect that NeuroBo Pharmaceuticals will post -4.89 earnings per share for the current fiscal year.

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity.